J Drugs Dermatol. 2023 Aug 1;22(8):SF381621s5-SF381621s10. doi: 10.36849/jdd.SF381621s5.
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with vitamin D analogs can produce synergistic effects and minimize adverse effects. However, due to the incompatible pH ranges of topical steroids and vitamin D analogs, combination formulations can be difficult to manufacture. Until recently, only anhydrous formulations of these 2 agents were developed as foam, gel/suspension, and ointment. However, anhydrous vehicles can often result in greasy or oily skin, thus limiting treatment adherence. Recently, Polyaphron Dispersion (PAD) technology presents a new, more cosmetically appealing vehicle that allows for both topical steroids and vitamin D analogs to coexist in an aqueous environment, such as a cream formulation. The calcipotriene/betamethasone dipropionate (CAL/BDP) cream enhances drug delivery by reducing the greasy and oily side effects of anhydrous formulations. Phase 3 clinical trials have demonstrated CAL/BDP cream’s superior efficacy in treating psoriasis over gel/suspension, and the clinical trials have also shown significantly improved patient satisfaction with the cream formulation.  .
大多数斑块型银屑病患者的疾病处于轻度至中度，局部治疗仍然是这些患者的主要治疗选择。局部类固醇与维生素 D 类似物联合使用可以产生协同作用，并最大限度地减少不良反应。然而，由于局部类固醇和维生素 D 类似物的 pH 值范围不兼容，联合制剂的生产可能具有挑战性。直到最近，这两种药物的无水制剂才被开发为泡沫剂、凝胶/混悬剂和软膏剂。然而，无水载体往往会导致皮肤油腻或油性，从而限制了治疗的依从性。最近，Polyaphron Dispersion（PAD）技术提供了一种新的、更具吸引力的载体，可使局部类固醇和维生素 D 类似物共存于水性环境中，如乳膏制剂。卡泊三醇/倍他米松二丙酸酯（CAL/BDP）乳膏通过减少无水制剂的油腻和油性副作用来增强药物递送。3 期临床试验表明，CAL/BDP 乳膏在治疗银屑病方面优于凝胶/混悬剂，临床试验还表明，患者对乳膏制剂的满意度显著提高。
